18 results with keyword: 'multiple sclerosis treatments interferon glatiramer acetate fingolimod natalizumab'
A REVIEW OF MULTIPLE SCLEROSIS TREATMENTS: INTERFERON BETA, GLATIRAMER ACETATE, FINGOLIMOD, AND NATALIZUMAB Abstract3. Multiple Sclerosis (MS) is an autoimmune disease in
N/A
The NHS Commissioning Board (NHS CB) will commission Beta interferon, glatiramer acetate, natalizumab and fingolimod for the management of Multiple Sclerosis (MS) according to
N/A
Disability state a Relapsing remitting multiple sclerosis: treatment with interferon beta-1a, interferon beta-1b or glatiramer acetate Secondary progressive multiple
N/A
Comparison of subcuta- neous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing
N/A
Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing remitting multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS
N/A
Comparison of interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis, the Rebif versus glatiramer acetate in relapsing MS Disease (REGARD) study),
N/A
Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs glatiramer acetate in relapsing MS disease
N/A
Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relaps- ing multiple sclerosis (the REbif vs Glatiramer Acetate in Relaps- ing MS
N/A
Methods: Patients with relapsing multiple sclerosis currently receiving subcutaneous or intramuscular interferon beta-1a, interferon beta-1b, or glatiramer acetate
N/A
It reflects on the Declaration Dialogues that have been held by the Australian Human Rights Commission and the National Congress of Australia’s First Peoples in Aboriginal and
N/A
Demographic (age, sex), clinical (MS-phenotype, disability), and DMT (untreated, alemtuzumab, cladribine, dimethyl-fumarate, glatiramer acetate, interferon, natalizumab,
N/A
First-line Agents (lower risk) Second-line Agents (higher risk) Interferon beta-1a Interferon beta-1b Glatiramer acetate Oral therapies: Fingolimod Teriflunomide Dimethyl
N/A
FDA-approved therapies (Approval time period) 1995 2000 2005 2009 2010 2011 Extavia (IFNβ-1b) Gilenya (fingolimod) Tysabri (natalizumab) Betaseron (IFNβ-1b) Copaxone
N/A
At present the only disease modifying therapies available for relapsing remitting and secondary progressive multiple sclerosis are interferon beta and glatiramer acetate, which
N/A
Interferon beta (IFN-β) and glatiramer acetate (GA) are the primary therapeutic immunomodulatory agents that interfere with relapsing-remitting multiple sclerosis (RRMS), and
N/A
Conclusions: The treatment of relapsing-remitting multiple sclerosis with glatiramer acetate entailed cost savings when compared to interferon- β in patients with spasticity, which
N/A
reader but is not intended to be a substitute for legal or medical advice. MS Australia is not recommending medical or legal advice and readers must seek their own medical or
N/A
Revised guidelines for the use of interferon and glatiramer acetate in multiple sclerosis, published in 2007, were designed to supplement rather than supplant the 2001
N/A